News

In The News

Articles, research coverage, and media featuring Dr. Sai Chavala and Retina of North Texas.

Featured news · 2026 Nobel Prize in Physiology or Medicine

Nobel Prize honors optogenetics, the science behind an investigational therapy Dr. Chavala helped develop

The 2026 Nobel Prize recognized the discovery of light-gated ion channels and optogenetics, the foundational work of Karl Deisseroth, Peter Hegemann and Georg Nagel. Nanoscope Therapeutics used optogenetics to develop MCO-010, an investigational gene therapy for retinitis pigmentosa now under FDA review. Dr. Chavala served as Nanoscope’s first Chief Medical Officer and was an investigator in its clinical development.

Featured article · D Magazine

Has Dr. Sai Chavala Just Found the Cure for Macular Degeneration?

A profile of Dr. Chavala's research in cellular reprogramming and future-oriented vision restoration. We present it humbly as part of the broader scientific effort to develop better options for patients with blinding retinal disease.

Read Featured Article
Research videos

Research and media videos

Selected video coverage and research media related to Dr. Chavala’s retina research and vision-restoration work.

YouTube

Research video featuring Dr. Sai Chavala

A selected video link provided for the research and media section.

Open on YouTube
Articles & media

Research and retina care coverage

Links are collected from the current Retina of North Texas news page and additional requested media coverage.

Dallas Business Journal

Dr. Chavala featured as “Top Innovator” in the Dallas Business Journal

North Texas innovation coverage highlighting research projects shaping the future.

Read More
PR Newswire

Sai Chavala, M.D., Receives ARVO Foundation Ludwig von Sallmann Clinician-Scientist Award

Recognition from the ARVO Foundation for clinician-scientist impact.

Read More
TCU Magazine

Reprogramming Cells Could Restore Vision

Feature story on research focused on restoring vision in macular degeneration.

Read More
ScienceDaily

Researchers restore sight in mice by turning skin cells into light-sensing eye cells

Science coverage of direct cellular reprogramming work.

Read More
American Academy of Ophthalmology

In 10 Days: From Skin Cells to Photoreceptors

AAO EyeNet coverage of photoreceptor-like cell development.

Read More
Nature

Pharmacologic fibroblast reprogramming into photoreceptors restores vision

Original Nature publication on pharmacologic reprogramming into photoreceptor-like cells.

Read More
New England Journal of Medicine / PubMed

Sourcing Photoreceptor-like Cells for Treating Vision Loss

NEJM commentary indexed on PubMed.

Read More
Dallas Morning News

Dr. Chavala on artificial tear eye drop concerns

Patient-facing safety commentary on recalled artificial tear drops.

Read More
Ophthalmology Times

How MCO-010's 3-year data are redefining what's possible for advanced retinal degeneration

Additional retina specialist media coverage requested for the news page.

Read More
Associated Press

Dr. Chavala comments on Tony Romo's eye condition

Associated Press coverage featuring Dr. Chavala's perspective on Tony Romo's eye condition.

Read More
Ophthalmology Times

Dr. Chavala discusses MCO-010's 3-year retinal data

An exclusive Q&A on sustained vision-restoration results at 3 years, with Dr. Chavala speaking as a clinical trial investigator alongside Stanford's Dr. Vinit Mahajan.

Read More
PR Newswire

FDA accepts Nanoscope's MCO-010 BLA for review, a therapy Dr. Chavala helped develop

The FDA has accepted Nanoscope Therapeutics' Biologics License Application for MOGENRY (MCO-010). Dr. Chavala served as Nanoscope's first Chief Medical Officer and was an investigator in the clinical development of MCO-010.

Read More
Peer-reviewed publications

Dr. Chavala co-authors two peer-reviewed publications on MCO-010 optogenetic therapy

The STARLIGHT Phase 2 trial in Stargardt disease (EClinicalMedicine, 2025) and “A synthetic opsin restores vision in patients with severe retinal degeneration” (Molecular Therapy, 2025). Both describe investigational therapy studied in clinical research.

STARLIGHT Trial PaperSynthetic Opsin Paper

Disclosure: Dr. Chavala served as Nanoscope Therapeutics' first Chief Medical Officer and has served as a consultant and advisor to the company. MCO-010 is investigational and has not been approved by the FDA.